Effect of Pioglitazone on T2DM Patients With COVID-19

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1506 participants.

Also called NCT04604223

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,506 participants (planned count) (from the registry)
Sponsor
Dasman Diabetes Institute (from the registry)
Registry
  • NCT NCT04604223
Other papers using this trial's data
  • Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial Frontiers in immunology, 2024 DOI, PubMed 39308871, PMC11412854 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Kuwait, Qatar (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04604223. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-18 (actual); primary completion 2021-06-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Pioglitazone on T2DM Patients With COVID-19
Acronym
PIOQ8
Condition
Covid19
Intervention (Drug)
Pioglitazone 45 mg
Lead sponsor
Dasman Diabetes Institute (class: other)
Collaborator
Ministry of Health, Kuwait (class: other government)
Collaborator
Texas Diabetes Institute (class: other)
Collaborator
Kuwait University (class: other)

Record details

Record id
cardio:ct-nct04604223
Content hash
a155ecfd6dd1d9b04fe73e2d2541bc845e04d1ff36407b5986f012bc154e5853